Quantcast

Latest Rituximab Stories

2014-03-12 23:24:38

Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh, NC (PRWEB) March 12, 2014 According to the Non-Hodgkin’s Lymphoma Center, a study published in the journal Blood suggests that patients with certain kinds of Non-Hodgkin’s Lymphomas may get equally good results from a new chemotherapy combination than from the standard drugs. Researchers at the Sarah Cannon Research Institute...

2014-02-27 04:20:49

- Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy - SEATTLE, Feb. 27, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published...

2014-02-22 23:01:25

Careful screening is recommended to protect Non-Hodgkin’s Lymphoma patients against this dangerous side effect of rituximab. Raleigh, NC (PRWEB) February 22, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a newly-published article illustrating the potential dangers of rituximab therapy. Rituximab is a monoclonal antibody that is often used along with traditional chemotherapy in the treatment of Non-Hodgkin’s Lymphoma and other cancers involving the immune system B-cells....

2014-02-20 16:25:31

Company launches its first product, IMBRUVICA(TM), and records net product revenue of $13.6 million SUNNYVALE, Calif., Feb. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December 31, 2013. Financial Results for the Quarter and Year Ended December 31, 2013 Revenue Total revenue for the quarter ended December 31, 2013 increased 113% to $123.6 million, from $58.0 million for the...

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...

2014-01-31 10:46:34

In patients with a frequently-relapsing form of kidney disease, relapses decreased approximately five-fold for at least one year after patients took a single dose of rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis. The findings, which will appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggest that this drug may provide considerable benefits for patients. For most...

2014-01-24 12:23:26

SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera(®) (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)...

2014-01-24 11:25:34

Results on test of Idelalisib suggest CLL may be treated without toxic chemotherapy Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team. Their findings on the therapy for chronic lymphocytic leukemia (CLL), reported in the Jan. 22 issue of the New England Journal of Medicine, suggest that patients may be able to avoid having to take debilitating...

2014-01-13 08:30:25

SHANGHAI, Jan. 13, 2014 /PRNewswire/ -- ShangPharma Corporation is pleased to announce that Dr. Mitchell Reff has joined the company as Chief Biologics Officer. Dr. Reff brings over 30 years of research and development experience in the biopharmaceutical industry. Dr. Reff's appointment further strengthens the world-class technical capabilities of ChemPartner's Biologics Division and offers Pharmaceutical and Biotechnology companies from around the world first-rate strategic and...

2014-01-06 04:21:41

- PIXUVRI Deemed Cost Effective for Patients with Multiply Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - SEATTLE, Jan. 6, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related